Stati Uniti - inglese - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 60 mg - duloxetine delayed-release capsules are indicated for the treatment of: monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] . starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)] . teratogenic effects pregnancy category c risk summary — there are no adequate and well-controlled studies of duloxetine delayed-release capsules administr

Stati Uniti - inglese - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - duloxetine is indicated for the treatment of: monoamine oxidase inhibitors (maois) -the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] . starting duloxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)]. pregnancy category c risk summary — there are no adequate and well-controlled studies of duloxetine administration in pregnant women. in animal studies with duloxetine, fetal weights were decreased but there was no evidence of teratogenicity in pregnant rats and rabbits at oral do

Stati Uniti - inglese - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules are indicated for the treatment of: monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)] . pregnancy category c   risk summary there are no adequate and well-controlled studies of duloxetine administration in pregnant women. in animal studie

Stati Uniti - inglese - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine is indicated for the treatment of: - major depressive disorder [see clinical studies (14.1)] - generalized anxiety disorder [see clinical studies (14.2)] - diabetic peripheral neuropathy [see clinical studies (14.3)] - chronic musculoskeletal pain [see clinical studies (14.5)]         monoamine oxidase inhibitors (maois) -the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] .         starting duloxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)].         pregnancy

Canada - inglese - Health Canada

novartis pharmaceuticals canada inc - inclisiran (inclisiran sodium) - solution - 284mg - inclisiran (inclisiran sodium) 284mg

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage); nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) - powder for injection with diluent - 1000 iu - active: nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection active: nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage); nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) - powder for injection with diluent - 250 iu - active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection sodium chloride water for injection active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage); nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) - powder for injection with diluent - 500 iu - active: nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection active: nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

Israele - inglese - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tigecycline - powder for solution for infusion - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, clostridium perfringens, and peptostreptococcus micros.community-acquired bacterial pneumonia:community-acquired bacterial pneumonia caused by streptococcus pneumoniae (penicillin susceptible isolates), including cases with concurrent bacteremia, haemophilus influenzae (beta-lactamase negative isolates), and legionella pneumophila.

Stati Uniti - inglese - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. - naratriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of naratriptan tablets have not been established for cluster headache. naratriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1) ] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway d